Differential effects of lithium on muscarinic cholinoceptor-stimulated CMP-phosphatidate accumulation in cerebellar granule cells, CHO-M3 cells, and SH-SY5Y neuroblastoma cells.
The ability of lithium to potentiate muscarinic cholinoceptor-stimulated CMP-phosphatidate (CMP.PA) accumulation has been examined in various cells in which muscarinic cholinoceptor agonists evoke a phosphoinositide response. Cell types examined include rat cerebellar granule cells, Chinese hamster ovary cells transfected to express the human muscarinic M3 receptor (CHO-M3 cells), and SH-SY5Y neuroblastoma cells. Neither carbachol (1 mM) nor lithium (10 mM) caused significant increases in CMP.PA accumulation in rat cerebellar granule cells; however, when added together for 20 min a linear 17-fold increase over basal levels was observed. The increase was dependent on the concentration of carbachol and lithium present, and the effect could be reversed by addition of exogenous myo-inositol (10 mM). Addition of carbachol alone to CHO-M3 cells caused a five-fold increase in CMP.PA accumulation. In the presence of lithium, a 70-fold increase was observed at 20 min after carbachol plus lithium addition. This latter response was concentration dependent and could be abolished by preincubation in the presence of 10 mM myo-inositol. In contrast, whereas carbachol elicited a three-fold increase in CMP.PA accumulation in SH-SY5Y neuroblastoma cells, which reached a plateau 10 min after agonist addition, the response could neither be augmented by addition of lithium nor inhibited by addition of myo-inositol. These results emphasise that the ability of lithium to affect agonist-stimulated CMP.PA accumulation is not simply a function of stimulus strength, but is also crucially dependent on the intracellular concentration of inositol.
Gray
D W
DW
Department of Cell Physiology and Pharmacology, University of Leicester, England, U.K.
Challiss
R A
RA
Nahorski
S R
SR
D000818:Animals; D000831:Animals, Newborn; D016466:CHO Cells; D002217:Carbachol / Q000494:pharmacology*; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology / Q000378:metabolism*; D006224:Cricetinae; D003568:Cytidine Monophosphate / Q000031:analogs & derivatives* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D020404:Glycerophospholipids; D006801:Humans; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D007700:Kinetics; D008094:Lithium / Q000494:pharmacology*; D008297:Male; D009447:Neuroblastoma; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D010712:Phosphatidic Acids / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D020404:Glycerophospholipids; D010712:Phosphatidic Acids; D011976:Receptors, Muscarinic; C088379:cytidine monophosphorylphosphatidate; D015544:Inositol 1,4,5-Trisphosphate; D002217:Carbachol; D008094:Lithium; D003568:Cytidine Monophosphate